MapLight Therapeutics, Inc. (MPLT) vs NeoGenomics, Inc. (NEO)

A side-by-side comparison of MapLight Therapeutics, Inc. and NeoGenomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

MPLT

MapLight Therapeutics, Inc.

$411M

$9.69HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

NEO

NeoGenomics, Inc.

$424M

$16.51HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — MPLT vs NEO

growth of $100 · dividends reinvested · last 1y

MPLT -49.4% (-49.4%/yr)NEO +85.0% (+85.0%/yr)NEO compounded faster over this window

MPLT NEO

MPLT vs NEO: by the numbers

•NEO is the larger company ($424M vs $411M market cap).
•Both run net losses; MPLT's is the smaller (0.00% vs -6.77% net margin).

Metrics side by side

Valuation

Metric	MPLT	NEO
Forward P/E	N/A	90.32
P/S ratio	N/A	0.55
P/B ratio	1.18	0.54

Profitability

Metric	MPLT	NEO
Gross margin	0.00%	42.92%
Operating margin	0.00%	-8.63%
Net margin	0.00%	-6.77%
ROE	-65.99%	-6.60%
ROIC	-69.35%	-5.29%

Growth (annualized)

Metric	MPLT	NEO
Revenue CAGR (5Y)	N/A	9.41%
Total return CAGR (5Y)	N/A	-15.14%

Go deeper

Full MPLT analysis Full NEO analysis Interactive comparison tool

Dig into the metrics

MapLight Therapeutics ROE NeoGenomics ROE MapLight Therapeutics operating margin NeoGenomics operating margin MapLight Therapeutics revenue growth NeoGenomics revenue growth MapLight Therapeutics free cash flow NeoGenomics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.